气管黏膜厚度是评估鸡毒支原体疫苗免疫原性的优选方法
该研究比较了已发表疫苗效力试验中的气管黏膜厚度(TMT)与气囊病变评分(ALS)数据,发现基于TMT的分析能以更少的生物学重复检测到≥80%的攻击效力,且免疫攻击组中≥80%保护比例、病变减少≥30%及缓解分数≥0.80的比例显著更高。结论认为TMT是更具区分度和可重复性的参数,应作为评估鸡毒支原体疫苗效力的主要结局变量。
要点
- 基于TMT比ALS能以更少生物学重复检测到疫苗效力。
- TMT分析中免疫攻击组达到高保护比例的比例显著更高。
- TMT作为主要结局变量可减少所需动物数,提升动物福利。
核心结论
- TMT是评估鸡毒支原体疫苗效力和效力试验有效性的更优区分度和可重复性参数,应作为主要结局变量。
研究设计与样本
- 研究比较了已发表疫苗效力研究中的原始气管黏膜厚度(TMT)与气囊病变评分(ALS)数据。
主要发现
- 基于TMT的分析中,更高比例的试验检测到攻击的≥80%效力,且所需生物学重复数显著更低。
- 基于TMT时,免疫攻击组中保护比例≥80%、病变减少≥30%及缓解分数≥0.80的比例显著高于阳性对照组,且生物学重复数显著更低。
关键数值与推荐
- 原文报告以TMT为指标时,检测到≥80%攻击效力所需的生物学重复数显著低于ALS。
- 原文报告以TMT为指标时,免疫攻击组达到保护比例≥80%、病变减少≥30%和缓解分数≥0.80的比例显著高于阳性对照组。
临床怎么用
- 在鸡毒支原体疫苗效力评价中,优先采用气管黏膜厚度(TMT)作为主要结局指标。
- 使用TMT可减少效力试验所需动物数量,符合动物福利要求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Live-attenuated vaccines are commonly used to control chronic respiratory disease (CRD) caused by Mycoplasma gallisepticum in poultry. A previous review found that measures of tracheal lesions are better indicators of the validity of a vaccine efficacy test than air sac lesions. Here we extend those observations by comparing the raw tracheal mucosal thickness (TMT) and gross air sac lesion score (ALS) data from published vaccine efficacy studies to provide insights into standardising methods for evaluation of M. gallisepticum vaccine efficacy by identifying the most discriminative and reproducible parameter to demonstrate the efficacy of vaccines and the validity of immunogenicity tests. Our analyses revealed that a higher proportion of trials detected a ≥ 80 % effectiveness of challenge based on TMT, with a significantly lower number of biological replicates, than ALS. Furthermore, a significantly higher proportion of vaccinated-and-challenged groups had a proportion protected of ≥80 %, a reduction in lesions of ≥30 % and a mitigated fraction of ≥0.80, with a significantly lower number of biological replicates, compared to the positive-control group when analyses were based on TMT rather than ALSs. These findings indicate that TMT is a more discriminative and reproducible parameter to assess the efficacy of a vaccine and the validity of an efficacy test, and hence that this should be the primary outcome variable used to evaluate M. gallisepticum vaccine efficacy studies. Furthermore, the ability of TMT to discriminate these groups with fewer biological replicates enhances animal welfare by reducing the number of animals needed for efficacy studies.
引用
- Kulappu Arachchige SN, Abeykoon AMH, Stevenson MA, et al. Assessment of tracheal mucosal thicknesses is a preferable method for evaluation of the immunogenicity of Mycoplasma gallisepticum vaccines in poultry. Vaccine. 2025. PMID: 41365127. doi:10.1016/j.vaccine.2025.128063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。